Status:
COMPLETED
Rapid Rituximab Infusion at 90-minute Among Non-Hodgkin Lymphoma
Lead Sponsor:
National University Hospital, Singapore
Conditions:
Non Hodgkin Lymphoma
Eligibility:
All Genders
21+ years
Phase:
NA
Brief Summary
This is an observational prospective cohort study design to evaluate the safety of rapid Rituximab infusion at 90 minutes for Non-Hodgkin Lymphoma (NHL) patients. The secondary aim is to measure the n...
Detailed Description
The recommended guideline for Rituximab infusion for first cycle is to be commencing at an infusion rate of 50mg/hr for the first 30 minutes. If tolerated well, subsequent increments will step up to 5...
Eligibility Criteria
Inclusion
- The diagnosis of NHL is confirmed through histology report.
- Adult with age 21 years old and above
- Tolerated first and second cycles or at least two cycles of Rituximab infusion at recommended rate without Grade 3 or 4 adverse event during infusion
- Presence of any co-morbidity
- Ability to provide informed consent
Exclusion
- Subjects who diagnosed with NHL with high lymphocytes counts will be excluded from the study.
Key Trial Info
Start Date :
May 1 2012
Trial Type :
INTERVENTIONAL
Allocation :
ESTIMATED
End Date :
April 1 2013
Estimated Enrollment :
30 Patients enrolled
Trial Details
Trial ID
NCT01482754
Start Date
May 1 2012
End Date
April 1 2013
Last Update
December 10 2013
Active Locations (1)
Enter a location and click search to find clinical trials sorted by distance.
1
National University Hospital
Singapore, Singapore, Singapore, 119074